Non-Alcoholic Steatohepatitis Treatment Market Insights, Trends, Opportunities And Outlook 2033

The non-alcoholic steatohepatitis treatment global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

 

Non-Alcoholic Steatohepatitis Treatment Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

 

Market Size –

The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $1.89 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 38.7%.  The growth in the historic period can be attributed to rising prevalence of nash, growing awareness and diagnosis, lifestyle changes and obesity epidemic, clinical research, healthcare infrastructure and access, regulatory support and clinical trials.

 

The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%.  The growth in the forecast period can be attributed to advancements in drug development, increased disease awareness, rising prevalence and risk factor, shift towards personalized medicine. Major trends in the forecast period include patient-centric approach, technological advancements, targeted therapies, regulatory landscape, advancements in research.

 

Order your report now for swift delivery @

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

 

Scope Of Non-Alcoholic Steatohepatitis Treatment Market

The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

 

Non-Alcoholic Steatohepatitis Treatment Market Overview

Market Drivers –

An increased prevalence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market going forward. Insulin resistance occurs when muscles, fat, and liver cells do not respond adequately to insulin and cannot easily absorb glucose from the blood, causing high blood sugar. These are linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The use of insulin resistance has multiplied due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, according to a report from International Diabetes Federation, a Belgium-based global diabetes community, diabetes affects 537 million individuals (20-79 years old), accounting for one in every ten, which is expected to increase to 643 million by 2030 and 783 million by 2045. Furthermore, in March 2023, according to a report published by the Office for Health Improvement and Disparities, a UK government department, the number of premature deaths from liver disease witnessed a 3.7% increase, totaling 10,501 in 2021. Among these fatalities, 5,686 were attributed to alcohol-related liver disease in England, while non-alcoholic fatty liver disease accounted for 320 premature deaths.  Therefore, an increase in the prevalence of insulin resistance due to multiple liver and diabetes diseases will drive the non-alcoholic steatohepatitis treatment market.

 

Market Trends –

The development of the non-alcoholic steatohepatitis (NASH) drug is a key trend gaining popularity in the non-alcoholic steatohepatitis treatment market. Many companies are investing in developing innovative drugs for the treatment of liver diseases with reduced side effects of the drugs. For instance, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology company, received a grant from U.S. Food and Drug Administration (FDA) for fast-track designation to facilitate the development of the non-alcoholic steatohepatitis (NASH) drug, namely ervogastat and clesacostat. Fast Track is a process designed to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis named as; ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

 

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

 

Get an inside scoop of the non-alcoholic steatohepatitis treatment market, Request now for Sample Report @

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

 

Regional Insights –

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2023. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

 

Key Companies –

Major companies operating in the non-alcoholic steatohepatitis treatment market report are AstraZeneca Plc, Tobira Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Conatus Pharmaceuticals Inc., Novo Nordisk A/S, Immuron Ltd., Raptor Pharmaceutical Corp., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Gemphire Therapeutics Inc., Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Sinew Pharma Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG, Asahi Kasei Corporation

 

Table of Contents

1. Executive Summary
2. Non-Alcoholic Steatohepatitis Treatment Market Characteristics
3. Non-Alcoholic Steatohepatitis Treatment Market Trends And Strategies
4. Non-Alcoholic Steatohepatitis Treatment Market – Macro Economic Scenario
5. Global Non-Alcoholic Steatohepatitis Treatment Market Size and Growth

…………..

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Treatment Market
34. Non-Alcoholic Steatohepatitis Treatment Market Future Outlook and Potential Analysis
35. Appendix

 

List Of Tables:

Table 1: Global Historic Market Growth, 2018-2023, $ Billion

Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Table 3: Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 4: Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 5: Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

…………

Table 74: AstraZeneca Plc Financial Performance

Table 75: Tobira Therapeutics Inc. Financial Performance

Table 76: Galmed Pharmaceuticals Ltd. Financial Performance

Table 77: Genfit S.A. Financial Performance

Table 78: Zydus Cadila Healthcare Limited Financial Performance

 

Read Related Reports:

https://goodprnews.com/high-frequency-transformer-market-trend/

https://topprnews.com/green-technology-and-sustainability-market-size-2/

 

Learn About Us:

The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

 

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model